Barclays
LUMO

Barclays’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Barclays’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1
Closed – – 6541
2019
Q4 		$0 Sell
1
-1
-50% -$14 ﹤0.01% 6904
2019
Q3 		$0 Sell
2
-4,331
-100% -$63.5K ﹤0.01% 7219
2019
Q2 		$58K Buy
4,333
+3,351
+341% +$50.6K ﹤0.01% 6027
2019
Q1 		$17K Sell
982
-958
-49% -$14.3K ﹤0.01% 6417
2018
Q4 		$26K Buy
1,940
+368
+23% +$6.48K ﹤0.01% 5787
2018
Q3 		$34K Sell
1,572
-1,943
-55% -$59.1K ﹤0.01% 6270
2018
Q2 		$150K Sell
3,515
-3,987
-53% -$183K ﹤0.01% 4970
2018
Q1 		$488K Buy
7,502
+2,504
+50% +$177K ﹤0.01% 4008
2017
Q4 		$364K Sell
4,998
-4,204
-46% -$348K ﹤0.01% 4164
2017
Q3 		$843K Buy
9,202
+5,046
+121% +$387K ﹤0.01% 3164
2017
Q2 		$275K Sell
4,156
-6,037
-59% -$747K ﹤0.01% 4096
2017
Q1 		$2.21M Buy
10,193
+8,540
+517% +$1.22M ﹤0.01% 1997
2016
Q4 		$153K Buy
1,653
+1,594
+2,702% +$180K ﹤0.01% 4432
2016
Q3 		$8K Sell
59
-345
-85% -$34.3K ﹤0.01% 5879
2016
Q2 		$41K Sell
404
-584
-59% -$72.4K ﹤0.01% 4943
2016
Q1 		$160K Sell
988
-734
-43% -$149K ﹤0.01% 4007
2015
Q4 		$558K Buy
1,722
+850
+97% +$277K ﹤0.01% 3125
2015
Q3 		$275K Sell
872
-6,914
-89% -$3.04M ﹤0.01% 3879
2015
Q2 		$3.08M Sell
7,786
-9,316
-54% -$3.96M ﹤0.01% 1875
2015
Q1 		$8.31M Sell
17,102
-5,991
-26% -$2.32M 0.01% 1195
2014
Q4 		$8.11M Buy
23,093
+7,707
+50% +$2.29M 0.01% 1336
2014
Q3 		$2.91M Buy
15,386
+55
+0.4% +$12.1K ﹤0.01% 2313
2014
Q2 		$3.59M Buy
15,331
+545
+4% +$111K ﹤0.01% 2052
2014
Q1 		$3.72M Sell
14,786
-11,641
-44% -$3.56M ﹤0.01% 1956
2013
Q4 		$5.24M Sell
26,427
-1,333
-5% -$237K 0.01% 1789
2013
Q3 		$4.5M Buy
27,760
+15,648
+129% +$2.52M 0.01% 1769
2013
Q2 		$2.15M Buy
+12,112
New +$1.72M ﹤0.01% 2474

Other funds holding LUMO

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
IFG
Investors Financial Group Plymouth, Minnesota $215M AUM 19.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Barclays's LUMO Position: Q1 2020 in Review

Barclays sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q1 2020, closing a stake of 1 share.

Barclays first reported a position in LUMO in Q2 2013 and held it in 27 quarters. The position peaked at $8.31M in Q1 2015. 46 funds tracked by Wall St. Rank hold LUMO as of Q1 2020.

  • Barclays reported no remaining Lumos Pharma, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Barclays sold 1 Lumos Pharma, Inc. Common Stock share in Q1 2020.
  • Barclays first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 27 quarters.
  • Barclays's Lumos Pharma, Inc. Common Stock position peaked at $8.31M in Q1 2015.
  • 46 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q1 2020.

Based on Barclays's 13F filing for Q1 2020, filed 13 May 2020.